Scinai Stock Surges on $2.61 Million Private Placement as SCNI Bets on CDMO Expansion
Shares of Scinai Immunotherapeutics Ltd. surged Friday in U.S. trading, buoyed by news out of Jerusalem: the biotech secured a $2.61 million private placement plus a warrant inducement to help bankroll its contract drug-manufacturing expansion and targeted immunotherapy programs. The company's American Depositary Shares on Nasdaq soared roughly 82% to $0.8299, after peaking at $1.11 earlier.
